Vitamin trouble is going to fade

02/05/24 -"The issue is not yet completely resolved. During the call, the management expressed some optimism but emphasized the need to achieve synergies and reduce costs, given the challenging nature of the ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

02/05/24

Download

You may also be interested by these reports :

17/05/24

Utilities

Renewable Energy highlights – Some recent (political) news and its potential impact on renewable companies

15/05/24

Solvay

The Q1 figures were negatively affected by reduced sales prices, leading to a 14% decrease in sales and a 26% reduction in adjusted EBITDA. This was ...

14/05/24

Arkema

Sales in the Q1 declined as anticipated, but adjusted EBITDA demonstrated greater resilience. The figures were mixed compared to the consensus ...

14/05/24

Brenntag

1Q24 EBITA 24% down yoy – Full year EBITA at low end of expectations

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue

DSM-Firmenich